QUEST DIAGNOSTICS INC

Quest Diagnostics operates in the diagnostic information services industry, which is an essential healthcare service that the company believes will continue to grow over the long term. The industry is characterized by key trends including reimbursement pressure driven by the Protecting Access to Medicare Act of 2014, health plans driving value in lab spending, consumerization, prevention and wellness, medical innovation, healthcare industry evolution with a focus on value, pricing transparency, competition, healthcare utilization, reimbursement pressure and affordability, a changing legislative and regulatory environment, the use of healthcare data and technology including artificial intelligence, chronic diseases and gaps in care, and the shift of healthcare services delivery to new settings. The company estimates that annually it serves approximately half of the physicians and half of the hospitals in the United States, and the patients it serves annually comprise approximately one-third of the adult population of the United States, with over a three-year period serving approximately one-half of the adult population of the United States.

The company's primary competitors include other commercial clinical laboratories, with its largest commercial clinical laboratory competitor being Laboratory Corporation of America Holdings, Inc. It also competes with hospital-affiliated laboratories, physician-office laboratories, anatomic pathology practices, large physician group practices, and providers of consumer-initiated testing. The company believes its competitive advantages include providing the most attractive service offering in the industry with a comprehensive test menu, innovative test offerings, a positive customer experience, deep medical and scientific expertise, high quality, leading access and distribution, and data-powered integrated information-technology solutions. Through health plans, the company estimates it has access to over 90% of insured lives in the United States.

The company generates revenue primarily through its Diagnostic Information Services business, which provides diagnostic insights from laboratory testing to empower people, physicians, and organizations. Revenue is recognized primarily upon completion of the testing process or when services have been rendered, with estimates of consideration expected from payer customer groups using a portfolio approach. The company's primary customer channels are physicians, hospitals, and patients and consumers, with other customers including health plans, employers, new and emerging retail healthcare providers, government agencies, pharmaceutical companies, and other commercial clinical laboratories. The company also has a Diagnostic Solutions group that includes a risk assessment services business for insurers and healthcare information technology businesses for providers and payers.

The Diagnostic Information Services business provides an industry-leading menu of routine, non-routine, and advanced clinical testing and anatomic pathology testing. In 2025, certain Advanced Diagnostics test offerings within five clinical areas — oncology, cardiometabolic and endocrine, brain health, autoimmune, women's health and genetics — generated over $1 billion in revenues on double-digit revenue growth. The company offers broad access to clinical testing through a network of laboratories, including advanced laboratories and rapid response laboratories, operating 24 hours a day, 365 days a year. Its network also includes approximately 2,400 patient service centers, phlebotomists in physician offices, and connectivity resources including call centers and mobile phlebotomists. The company processed approximately 244 million test requisitions in 2025. In 2025, the company generated approximately $1.2 billion in revenue from reference testing for hospitals, and its Collaborative Lab Solutions offering generated approximately $800 million in revenues and management fees supporting hospitals in the operation of their own labs. The company's connectivity platform provides healthcare connectivity solutions to approximately 612,000 clinician and hospital accounts and interfaces with over 1,000 electronic health records systems. The company's MyQuest patient healthcare portal had more than 45 million registered users at year-end 2025. The company owns or controls approximately 1,200 issued and approximately 400 pending patents worldwide in 2025. The company's medical and scientific staff includes approximately 900 M.D.s and Ph.D.s, and it has approximately 25,000 phlebotomists, paramedics, nurses and other health and wellness professionals. The company's logistics capabilities include making over 83,000 stops daily, approximately 5,000 courier vehicles, and 18 aircraft serving the United States. The company has one of the world's largest databases of de-identifiable laboratory test results with over 80 billion patient data points.

The Diagnostic Solutions group includes the risk assessment service ExamOne, which is the largest provider of risk assessment services to the life insurance industry in North America, comprising underwriting support services including data gathering, paramedical examinations, and clinical laboratory testing and analytics. The company also offers Quanum Enterprise Content Solutions for hospitals, which are used at approximately 1,400 sites in North America. In 2024, the company acquired LifeLabs, a company that provides laboratory diagnostic information and digital health connectivity systems in Canada. During the full year of 2025, LifeLabs performed approximately 23 million test requisitions and operates approximately 15 laboratories and over 350 collection centers in British Columbia, Ontario and Saskatchewan.

During 2025, the company acquired select clinical testing and dialysis-related water testing assets of Fresenius Medical Care's wholly-owned Spectra Laboratories for $84 million of aggregate cash consideration. The company also entered into a joint venture with Corewell Health, with equity ownership shared 51% by Quest and 49% by Corewell Health. In February 2025, the company committed to a multi-year project called Project Nova to modernize its Order to Cash business processes, partnering with Epic, a third-party licensor, with completion expected in 2031 to 2032. In February 2026, the company announced an increase in its quarterly common stock cash dividend by approximately 7.5%, from $0.80 per common share to $0.86 per common share, representing its 15th increase since the beginning of 2012. Since the beginning of 2012, the company has returned approximately $8.1 billion to stockholders through repurchases of its common stock. In February 2026, the Board of Directors increased the size of the share repurchase program by $1 billion to $1.4 billion. For the year ended December 31, 2025, the company repurchased 2.5 million shares of its common stock for $452 million. During the year ended December 31, 2025, the company incurred $53 million of pre-tax charges in connection with restructuring and integration activities, including $28 million of employee separation costs. In 2025, the company received a breakthrough device designation from the FDA for its Haystack Oncology MRD test for patients with an early stage colorectal cancer diagnosis. The company also announced a collaboration with Google to use Google Cloud's data analytics and generative AI.

For the year ended December 31, 2025, the company generated net revenues of $11,035 million, compared to $9,872 million in 2024 and $9,252 million in 2023. Net income attributable to Quest Diagnostics was $992 million in 2025, compared to $871 million in 2024 and $854 million in 2023. Diluted earnings per share was $8.75 in 2025, compared to $7.69 in 2024 and $7.49 in 2023. Net cash provided by operating activities was $1,886 million in 2025, compared to $1,334 million in 2024 and $1,272 million in 2023. Operating income was $1,556 million in 2025, compared to $1,346 million in 2024 and $1,262 million in 2023.

A key growth vector is the company's focus on Advanced Diagnostics, which includes certain procedures in molecular diagnostics, oncology, neurology, companion diagnostics, and non-invasive pre-natal and other germline genetic testing. In 2025, certain Advanced Diagnostics test offerings within five clinical areas generated over $1 billion in revenues on double-digit revenue growth. The company is focused on the rapidly growing area of monitoring recurrence and therapy effectiveness, including through its acquisition of Haystack Oncology, which developed a highly sensitive testing technology for detecting minimal-residual disease by circulating tumor DNA. In 2025, the company received a breakthrough device designation from the FDA for its Haystack Oncology MRD test and commenced separate trials with Mass General Brigham and Rutgers Cancer Institute. The company also continues to focus on neurology, having launched its QUEST AD-Detect test portfolio for assessing Alzheimer's disease risk using blood specimens, and continues to publish evidence on this test. The company's growth strategy also includes generating growth through value-creating, strategically aligned acquisitions, with a goal to grow revenues each year by 1-2% through acquisitions.

Another growth vector is the company's focus on patients and consumers, including its QuestHealth.com platform which empowers consumers to purchase tests and panels without needing to visit a doctor's office, offering over 150 tests including comprehensive wellness panels with up to 85 key health indicators. The company is powering the testing offered by leading health, wellness, and wearable brands. The company also sees opportunities in its Collaborative Lab Solutions offering, which generated approximately $800 million in revenues and management fees in 2025, and in serving hospitals through reference testing, which generated approximately $1.2 billion in revenue in 2025. The company's international operations, including the acquisition of LifeLabs in Canada, represent another growth vector, with LifeLabs performing approximately 23 million test requisitions in the full year of 2025. The company also sees opportunities to bring its experience and expertise in diagnostic information services to markets outside the United States.

The company's Invigorate program aims to deliver 3% annual cost savings and productivity improvements to partially offset pressures from an inflationary environment, including labor and benefit cost increases, and reimbursement pressures. The company is leveraging automation and artificial intelligence to improve productivity and quality across its entire value chain. In February 2025, the company committed to Project Nova, a multi-year project to modernize its Order to Cash business processes, with total project-related cash expenditures estimated to be approximately $250 million to $310 million, with approximately 60% consisting of capital expenditures and the remainder consisting of operating expenses, to be incurred over the life of the project with final phases expected to be completed in the 2031 to 2032 timeframe. For 2026, total project-related cash expenditures are estimated to be approximately $60 million.

The company estimates it will invest approximately $550 million during 2026 for capital expenditures to support and grow its existing operations, principally related to investments in laboratory equipment and facilities, including laboratory automations and information technology to support its diagnostic offerings. The company has $500 million of 3.45% senior notes due June 2026. In February 2026, the company announced an increase in its quarterly common stock cash dividend by approximately 7.5%, from $0.80 per common share to $0.86 per common share. In February 2026, the Board of Directors increased the size of the share repurchase program by $1 billion to $1.4 billion. As of December 31, 2025, $0.4 billion remained available under the share repurchase authorization.

The company faces headwinds from ongoing inflationary pressures which have resulted in increases in the cost of its operations, including testing equipment, supplies, and other goods and services, as well as labor costs including compensation, benefits, and recruiting and training new hires. The company also faces reimbursement pressure from government payers, including the potential impact of the Protecting Access to Medicare Act of 2014, although Congress has repeatedly acted to delay PAMA implementation. The company faces headwinds from the One Big Beautiful Bill Act enacted in July 2025, which is expected to impact healthcare providers primarily through changes to Medicaid and the Affordable Care Act, with the company currently estimating that for 2026 through 2028 the OBBBA and the expiration of the enhanced Premium Tax Credits at the end of 2025 could reduce consolidated revenues by up to 50-60 basis points by 2028, compared to 2025. The company also faces headwinds from the trend of rising patient responsibility which has resulted in an increase in reserves for patient price concessions.

The company faces structural headwinds from the evolution of the U.S. healthcare system, including value-based reimbursement, consolidation among healthcare industry participants, and the shift of healthcare services to non-traditional providers and venues. The company also faces risks from the highly competitive nature of the clinical testing business, including competition from hospital-affiliated laboratories, physician-office laboratories, and new industry entrants. The company faces risks from the development of new technologies that could enable more convenient and cost-effective testing outside of commercial clinical laboratories, such as point-of-care testing, complex testing performed by hospitals, and home testing. The company also faces risks related to its international operations, including exposure to risks inherent in doing business in non-U.S. markets such as intellectual property protections, trade regulations, data privacy regulations, and challenges based on differing languages, cultures, and practices.

The company faces significant reimbursement pressure from government payers, as reimbursement rates for many clinical laboratory tests under Medicare were reduced during 2018-2020 pursuant to PAMA, and although Congress has delayed further implementation, the structural flaws of PAMA still need to be addressed to mitigate future excessive cuts. The company also faces efforts by non-governmental third-party payers, including health plans, to reduce utilization of and reimbursement for clinical testing services through increased use of prior authorization requirements, increased denial of coverage, and alternative payment models. The clinical testing business is highly competitive, with the company competing against other commercial clinical laboratories, hospital-affiliated laboratories, and physician-office laboratories, and the trend of hospitals acquiring physician practices may enhance clinician ties to hospital-affiliated laboratories. The company faces risks from the development of new technologies that could enable more convenient and cost-effective testing outside of commercial clinical laboratories, such as point-of-care testing, complex testing performed by hospitals, and home testing. The company's IT systems are subject to potential cyberattacks, tampering, or other security breaches, and although no cybersecurity incident during 2025 resulted in a material impact, the scope of any future incident cannot be predicted. As of December 31, 2025, the company had approximately $5.7 billion of debt outstanding, which may impair its financial and operating flexibility.

Management's message emphasizes the company's strategy to achieve two key goals: generate growth and optimize operating efficiency. The growth strategy focuses on continually developing solutions to meet the evolving needs of customers by providing high quality, innovative, convenient and affordable diagnostic testing insights and services using the company's scale and extensive reach. Management emphasizes driving growth by offering an industry-leading menu of testing and other services, collaborating with healthcare providers and partners to leverage broad access, leveraging data assets and services to improve population health and enable value-based care, and continuously improving quality and efficiency by leveraging the Quest Management System and embracing innovative technologies such as automation and artificial intelligence. Management also emphasizes the company's disciplined capital deployment framework, which includes investment in the business, dividends, and share repurchases, grounded in maintaining an investment grade credit rating, with an expectation to return a majority of free cash flow to stockholders through a combination of dividends and share repurchases over time. Consistent with that expectation, in February 2026, the company announced it increased its quarterly common stock cash dividend by approximately 7.5%, from $0.80 per common share to $0.86 per common share.